MCL1

Across TCGA pan-cancer cohorts, MCL1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MCL1 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MCL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MCL1 expression acts as an unfavorable survival marker.

LIHC, ESCA, and UCEC are the cancer types where MCL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.010	0.716	<.001	18	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	III,IV	0.177	0.549	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MCL1–LIHC (OS)

Open the LIHC breakdown →